Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. [electronic resource]
Producer: 20070511Description: 1299-304 p. digitalISSN:- 1526-632X
- Adolescent
- Adult
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Brain -- drug effects
- Contrast Sensitivity -- drug effects
- Double-Blind Method
- Female
- Humans
- Immunosuppressive Agents -- administration & dosage
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting -- complications
- Natalizumab
- Neurologic Examination -- methods
- Placebos
- Predictive Value of Tests
- Treatment Outcome
- Vision Tests -- methods
- Vision, Low -- drug therapy
- Visual Acuity -- drug effects
- Visual Pathways -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.